RT Journal Article
SR Electronic
T1 Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2831
OP 2840
DO 10.21873/invivo.12570
VO 35
IS 5
A1 KOKI KATO
A1 TOMOHIRO MIZUNO
A1 TAKENAO KOSEKI
A1 YOSHIMASA ITO
A1 MASAKAZU HATANO
A1 KAZUO TAKAHASHI
A1 SHIGEKI YAMADA
A1 NAOTAKE TSUBOI
YR 2021
UL http://iv.iiarjournals.org/content/35/5/2831.abstract
AB Background/Aim: Concomitant proton pump inhibitor (PPI) and immune checkpoint inhibitor (ICPI) were determined as risk factors of acute kidney injury. To identify the type of PPI associated with ICPI-induced nephritis, we used the Japanese Adverse Drug Event Report database. Patients and Methods: ICPIs (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, and avelumab) and PPIs (esomeprazole, omeprazole, vonoprazan, rabeprazole, and lansoprazole) were selected as suspected nephritis-inducing drugs. Results: The cases of concomitant use of atezolizumab and rabeprazole, ipilimumab and omeprazole, ipilimumab and lansoprazole, nivolumab and esomeprazole, nivolumab and omeprazole, nivolumab and rabeprazole, nivolumab and lansoprazole, pembrolizumab and esomeprazole, as well as pembrolizumab and lansoprazole had a significantly higher reported odds ratio than monotherapy cases. Conclusion: Male patients or patients using ICPIs and PPIs (excluded vonoprazan) concomitantly should be monitored for renal function after chemotherapy.